Connect with us

Technology

National Security Commission on Emerging Biotechnology Urges Swift Action to Protect U.S. National Security

Published

on

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition.

WASHINGTON, April 8, 2025 /PRNewswire/ — Today, the National Security Commission on Emerging Biotechnology delivered its major report and action plan to Congress. The Commission’s top assessment is that urgent Congressional action is needed to bring the full weight of American innovation to bear on the biotechnology challenge and maintain U.S. global leadership in this transformative area.

Read the report here: www.biotech.senate.gov/final-report

For decades, the U.S. has been the global leader in biotechnology innovation. Now, the Commission finds that the U.S. is dangerously close to falling behind China.

The United States is locked in a competition with China that will define the coming century. Biotechnology is the next phase in that competition. It is no longer constrained to the realm of scientific achievement. It is now an imperative for national security, economic power, and global influence. Biotechnology can ensure our warfighters continue to be the strongest fighting force on tomorrow’s battlefields, and reshore supply chains while revitalizing our manufacturing sector, creating jobs here at home.” -NSCEB Chair Senator Todd Young

The Commission reports that the United States’ growing dependence on China for numerous critical supply chain elements is a national security vulnerability. Biotechnology can be the key to increasing supply chain security, resilience, and scalability, by allowing the U.S. to control its own access to critical components.

“Technology is not inherently good or bad, but who uses it matters. Biotechnology can have tremendous potential for good or tremendous potential for harm. The Chinese government has made biotechnology a strategic national priority for 20 years. The U.S. must reassert our global leadership to remedy this strategic weakness. We must be the ones driving the standards for how biotechnology is developed and used” -NSCEB Vice Chair Dr. Michelle Rozo

The Commission finds that emerging biotechnology is rapidly advancing, and the impact of biotechnology innovation already extends far beyond health, touching industries from agriculture and infrastructure, to manufacturing and defense. The intersection of artificial intelligence (AI) and biotechnology is accelerating this impact.

“Biotechnology holds immense potential to transform numerous key sectors of our economy and will create good paying jobs at all skill levels in agriculture, health care, defense, industrial manufacturing, and more. I am proud to be part of this commission that is ensuring the United States maintains our national security and economic competitive advantages as biotechnology grows across industries.” -NSCEB Commissioner Senator Alex Padilla

The Commission reports that biotechnology will drive the next wave of battlefield innovation, used to secure supply chains, enhance readiness, streamline logistics, improve resilience, and counter biological threats before they emerge.

“As emerging technologies transform the national security landscape, both the United States and our adversaries are gaining new capabilities. The United States must take the lead in biotechnology and propel us ahead of China in the 21st century.” -NSCEB Commissioner Representative Stephanie Bice 

The Commission’s assessment is that the future of American biotechnology leadership is only possible through strategic federal action that encourages innovation by spurring private investment. This includes targeted investments and strategic government reforms to reduce regulatory bottlenecks.

“We must embolden the best and brightest in biotechnology to innovate boldly. American ingenuity is stifled by outdated regulations in this sector. Only Congress can open the door to the American-led biotechnological future.” -NSCEB Commissioner Representative Ro Khanna 

The Commission’s report lays out six pillars for action and makes 49 recommendations. Full details can be found at www.biotech.senate.gov/final-report

Pillar 1: Prioritize biotechnology at the national levelPillar 2: Mobilize the private sector to get U.S. products to scalePillar 3: Maximize the benefits of biotechnology for defensePillar 4: Out-innovate our strategic competitorsPillar 5: Build the biotechnology workforce of the futurePillar 6: Mobilize the collective strengths of our allies and partners

Scheduling note:
HASC Subcommittee on Cyber, Information Technologies, and Innovation hearing on: Final Report of the National Security Commission for Emerging Biotechnology
Witnesses: NSCEB Chair Young and Vice Chair Rozo
Date/Time: Tuesday, April 8th at 4:00pm ET

About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the biorevolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit https:// biotech.senate.gov.

Contact: press@biotech.senate.gov

View original content to download multimedia:https://www.prnewswire.com/news-releases/national-security-commission-on-emerging-biotechnology-urges-swift-action-to-protect-us-national-security-302422627.html

SOURCE National Security Commission on Emerging Biotechnology

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

InventHelp®’s VIBE to Exhibit at Licensing Expo 2025

Published

on

By

PITTSBURGH, May 15, 2025 /PRNewswire/ — InventHelp’s Virtual Invention Browsing Experience, VIBE, will be exhibiting at Licensing Expo 2025 in Las Vegas, Nevada.

Licensing Expo is the world’s largest licensing trade show. The show will once again open its doors to attendees May 20-22, 2025, at the Mandalay Bay Convention Center. Companies registered to exhibit this year include Mattel, Paramount, Minecraft, Coca-Cola, and more.

Among these exhibitors, InventHelp® will once again present VIBE, a confidential technology platform allowing qualified companies to review InventHelp® client invention ideas.

VIBE features InventHelp client ideas with large 3D display touchscreen renderings and detailed descriptions that brand owners, product developers, licensees, merchandisers and other qualified companies can view in private viewing stations.

Enter VIBE at booth S226 as a qualified attendee for a chance to win a KitchenAid stand mixer along with a set of three MixAid silicone inserts for your stand mixer bowl.

“Future of Retail”, this year’s keynote speaking event, will feature a panel of retail representatives from companies including Walmart and Primark. The show floor is open to attendees starting Tuesday May 20th at 9 am.

Media Contact:  
Maria Jones
mjones@inventhelp.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inventhelps-vibe-to-exhibit-at-licensing-expo-2025-302457290.html

SOURCE InventHelp

Continue Reading

Technology

Gen Announces Board Transitions, Welcomes John Chrystal as Peter Feld Departs

Published

on

By

TEMPE, Ariz. and PRAGUE, May 15, 2025 /PRNewswire/ — Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, today announced the departure of Peter Feld from its Board of Directors, following his impactful tenure that began in 2018. With this departure, Gen welcomes John Chrystal, former member of MoneyLion’s Board of Directors, who joins the Gen Board as the Company accelerates its innovation and focus on financial wellness.

Peter Feld has been an extraordinary force behind Gen’s evolution. Joining the board of Symantec in 2018, Peter played an integral role in transforming the Company. His leadership was instrumental in the creation of NortonLifeLock, the subsequent merger with Avast, and the birth of Gen as a global consumer Cyber Safety brand and category leader.

“Peter has been a crucial partner and an invaluable asset to Gen,” said Frank Dangeard, Chair of Gen’s Board of Directors. “His vision and commitment have been central to shaping our strategy and setting the foundation for our growth. His legacy will always remain a part of Gen’s DNA as we look toward a future of empowering every individual to live their digital life confidently and securely. On behalf of the entire team, I want to extend my deepest gratitude to Peter for his contributions.”

Peter Feld said, “After serving for six years, it is time for me to step down from the Board. It has been an incredible journey, and I am thankful to Vincent, the entire management team, and the Board of Directors for their commitment to Gen and hard work towards delivering results and value creation. Gen is extremely well-positioned for the future with a strong foundation and exciting new growth prospects through its evolution into financial wellness. I look forward to watching the company continue to thrive.”

Gen also introduces John Chrystal to its Board of Directors. With extensive expertise in fintech and financial innovation, John’s leadership comes at a pivotal time following Gen’s acquisition of MoneyLion, where he served as Chair of the Board of Directors. His appointment signals Gen’s deepening commitment to expanding its portfolio in financial wellness, enabling consumers to safeguard both their digital lives and their financial future. John’s experience will directly contribute to Gen’s renewed mission, extending beyond Cyber Safety, to include financial wellbeing.

John Chrystal adds, “I am excited and humbled to join the extraordinary management and Board team at Gen. I look forward to all the ways I can contribute to the company as it pursues its important mission. In today’s world, trust-based solutions for digital and financial wellness are incredibly important. I look forward to aiding consumers as they strive to make the best financial choices possible, all while safeguarding their financial and digital future.” 

With these transitions, Gen stands at the forefront of industry innovation, laser-focused on delivering unparalleled value to consumers across its family of trusted brands.

About Gen 
Gen (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted consumer brands including Norton, Avast, LifeLock, MoneyLion and more. The Gen family of consumer brands is rooted in providing financial empowerment and cyber safety for the first digital generations. Today, Gen empowers people to live their digital lives safely, privately and confidently for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy, identity protection and financial wellness to nearly 500 million users in more than 150 countries. Learn more at GenDigital.com. 

CONTACTS

Investor Contact

Jason Starr

Media Contact

Jess Monney

Gen

Gen

IR@GenDigital.com

Press@GenDigital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gen-announces-board-transitions-welcomes-john-chrystal-as-peter-feld-departs-302457250.html

SOURCE Gen Digital Inc.

Continue Reading

Technology

Light AI Reports Financial Results for Q1 2025

Published

on

By

VANCOUVER, BC, May 15, 2025 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence (“AI”) health diagnostic and wellness solutions, today announced its financial and operating results for its first quarter of 2025 representing the three months ended March 31, 2025.   Financial information is reported in Canadian dollars (“$”) unless otherwise stated and in accordance with International Financial Reporting Standards (“IFRS”).

Financial and Operating Results Summary for Q1 2025

The Company is currently in the development stage of its software technology offering which is anticipated to be completed with related commercialization commencing in Q3 2025. During the three months ended March 31, 2025, the Company had total operating expenses, exclusive of interest, depreciation and share based payments, of approximately $4.2 million compared to approximately $1.4 million in the three months ended March 31, 2024 with the increase primarily attributable to the Company’s continued investment in product development with total research and development expenses of approximately $1.2 million in Q1 2025 compared to approximately $919,000 in the prior year period in addition to marketing and investor relations activities.

The Company had cash of $11.9 million as of March 31, 2025 compared to $15.2 million as of December 31, 2025.  On January 8, 2025, the Company closed the second of two tranches of the Offering by issuing 2,757,000 units of the Company at $0.55 per unit for aggregate gross proceeds of $1,516,350. The Company had Adjusted Working Capital of $12.6 million as of March 31, 2025 compared to $14.6 million as of December 31, 2025.

“Light AI has made strong progress throughout the first quarter of 2025, inclusive of going public with the completion of related equity financings totaling $18.5 million and strengthening our leadership team with the appointments of Anthony Schaller as President and CTO, John Tse as VP Commercial Development and George Reznik as CFO,” stated Peter Whitehead, CEO of Light AI. “We are committed to commercializing the Company’s AI oriented health and wellness software application in Q3 2025 to address various medical conditions including Strep A, COVID19 and Conjunctivitis (pink eye) to capitalize on our sizable market opportunity leveraging Light AI’s first mover advantage with our innovative, patented and disruptive technology.”

Financial Statements and Management Discussion & Analysis

Please see the Company’s consolidated financial statements (“Financial Statements”) and related Management’s Discussion & Analysis (“MD&A”) for more details. The Financial Statements for the three months ended March 31, 2025, and related MD&A have been reviewed and approved by the Company’s Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed on SEDAR+ at www.sedarplus.ca and is also available on the Company’s website at www.light.ai.

Non-IFRS and Other Financial Measures 

This press release refers to the following non-IFRS measures:

“Adjusted Working Capital” is comprised as current assets less current liabilities. Management believes Adjusted Working Capital is a useful indicator for investors, and is used by management, for evaluating the operating liquidity to the Company. See “Adjusted Working Capital Reconciliation” for a quantitative reconciliation of Adjusted Working Capital to the most directly comparable financial measure.

Such non-IFRS measures and non-IFRS ratio do not have a standardized meaning under IFRS and may not be comparable to a similar measure disclosed by other issuers.

Adjusted Working Capital Reconciliation

                                                                                                        March 31, 2025                  December 31, 2024
                Current Assets                                                                   $14,970,514                        $17,126,245
                Less: Current Liabilities                                                    (   2,352,273)                       (   2,481,677)
                Adjusted Working Capital                                                  $12,618,241                         $14,644,568

About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI’s vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes. Light AI’s commercial launch of its consumer-facing Wellness App initial offering is anticipated to be available in North America in Q3 2025.

ON BEHALF OF THE COMPANY

“George Reznik”
George Reznik
Chief Financial Officer
Telephone: 604-307-6800
Email: greznik@light.ai

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the Company’s research and development and commercialization initiatives, the anticipated inflection of the business, the Company’s financial and operational performance and outlook and other statements that contain words such as “believe,” “expect,” “project,” “should,” “seek,” “anticipate,” “will,” “intend,” “positioned,” “risk,” “plan,” “may,” “estimate” or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release.  For a list of the factors that may affect any of the Company’s forward-looking statements, please refer to the Company’s annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca). Light AI disclaims any intention or obligation to update or revise any forward-looking information contained in this news release, whether as a result of new information, future events or otherwise, unless required by applicable law. The forward-looking information included in this news release is expressly qualified in its entirety by this cautionary statement.

SOURCE Light AI Inc.

Continue Reading

Trending